Advanced Enzyme Technologies Share Price
Sector: Biotechnology & Drugs
329.00 +4.20 (1.29%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
327.00
Today’s High
337.45
52 Week Low
257.85
52 Week High
571.15
329.75 +5.20 (1.60%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
325.50
Today’s High
338.15
52 Week Low
257.90
52 Week High
571.00
Key Metrics
- Market Cap (In Cr) 3678.62
- Beta 0.77
- Div. Yield (%) 1.6
- P/B 2.56
- TTM P/E 23.84
- Peg Ratio 8.98
- Sector P/E 18.02
- D/E 0
- Open Price 327
- Prev Close 324.8
Advanced Enzyme Technologies Analysis
Price Analysis
-
1 Week-1.55%
-
3 Months17.12%
-
6 Month-8.22%
-
YTD-6.83%
-
1 Year-13.94%
Risk Meter
- 35% Low risk
- 35% Moderate risk
- 35% Balanced Risk
- 35% High risk
- 35% Extreme risk
Advanced Enzyme Technologies News
Buy or sell: Vaishali Parekh recommends three stocks for today — December 10
2 min read . 10 Dec 2024Diwali 2024 Picks: Reliance, BEML among 5 stocks to buy for Samvat 2081
2 min read . 31 Oct 2024THESE 11 companies are Progressive Shares' top technical picks for September
5 min read . 03 Sep 2024Q1 Results Today: Accel, APL Apollo Tubes among 137 companies to post earnings
2 min read . 10 Aug 2024Advanced Enzyme Technologies Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 636.91
- Selling/ General/ Admin Expenses Total
- 141.54
- Depreciation/ Amortization
- 36.56
- Other Operating Expenses Total
- 149.07
- Total Operating Expense
- 479.03
- Operating Income
- 157.88
- Net Income Before Taxes
- 187.36
- Net Income
- 131.12
- Diluted Normalized EPS
- 11.71
- Period
- 2025
- Total Assets
- 1621.35
- Total Liabilities
- 200.48
- Total Equity
- 1420.86
- Tangible Book Valueper Share Common Eq
- 92.52
- Period
- 2025
- Cashfrom Operating Activities
- 142.5
- Cashfrom Investing Activities
- -89.1
- Cashfrom Financing Activities
- -72.54
- Net Changein Cash
- -19.53
- Period
- 2024
- Total Revenue
- 623.87
- Selling/ General/ Admin Expenses Total
- 218.53
- Depreciation/ Amortization
- 35.24
- Total Operating Expense
- 469.46
- Operating Income
- 154.41
- Net Income Before Taxes
- 187.82
- Net Income
- 133.31
- Diluted Normalized EPS
- 12.92
- Period
- 2024
- Total Assets
- 1535.46
- Total Liabilities
- 199.1
- Total Equity
- 1336.37
- Tangible Book Valueper Share Common Eq
- 85.2
- Period
- 2024
- Cashfrom Operating Activities
- 141.37
- Cashfrom Investing Activities
- -64.65
- Cashfrom Financing Activities
- -59.24
- Net Changein Cash
- 17.33
- Period
- 2023
- Total Revenue
- 540.64
- Selling/ General/ Admin Expenses Total
- 198.68
- Depreciation/ Amortization
- 35.03
- Total Operating Expense
- 419.71
- Operating Income
- 120.93
- Net Income Before Taxes
- 140.39
- Net Income
- 105.64
- Diluted Normalized EPS
- 9.81
- Period
- 2023
- Total Assets
- 1421.85
- Total Liabilities
- 175.16
- Total Equity
- 1246.69
- Tangible Book Valueper Share Common Eq
- 77.35
- Period
- 2023
- Cashfrom Operating Activities
- 140.38
- Cashfrom Investing Activities
- -298.18
- Cashfrom Financing Activities
- -25.8
- Net Changein Cash
- -170.94
- Period
- 2022
- Total Revenue
- 529.38
- Selling/ General/ Admin Expenses Total
- 172.56
- Depreciation/ Amortization
- 34.98
- Other Operating Expenses Total
- 5.81
- Total Operating Expense
- 362.9
- Operating Income
- 166.48
- Net Income Before Taxes
- 171.06
- Net Income
- 119.58
- Diluted Normalized EPS
- 10.62
- Period
- 2022
- Total Assets
- 1267.61
- Total Liabilities
- 170.26
- Total Equity
- 1097.35
- Tangible Book Valueper Share Common Eq
- 65.74
- Period
- 2022
- Cashfrom Operating Activities
- 122.29
- Cashfrom Investing Activities
- -3.79
- Cashfrom Financing Activities
- -48.5
- Net Changein Cash
- 75.44
- Period
- 2021
- Total Revenue
- 501.84
- Selling/ General/ Admin Expenses Total
- 130.91
- Depreciation/ Amortization
- 28.41
- Other Operating Expenses Total
- 4.85
- Total Operating Expense
- 294
- Operating Income
- 207.84
- Net Income Before Taxes
- 210.37
- Net Income
- 146.2
- Diluted Normalized EPS
- 12.77
- Period
- 2021
- Total Assets
- 1156.17
- Total Liabilities
- 185.23
- Total Equity
- 970.94
- Tangible Book Valueper Share Common Eq
- 54.38
- Period
- 2021
- Cashfrom Operating Activities
- 163.49
- Cashfrom Investing Activities
- -26.03
- Cashfrom Financing Activities
- -26.31
- Net Changein Cash
- 109.26
- Period
- 2020
- Total Revenue
- 443.99
- Selling/ General/ Admin Expenses Total
- 125.78
- Depreciation/ Amortization
- 25.78
- Other Operating Expenses Total
- 4.39
- Total Operating Expense
- 267.11
- Operating Income
- 176.88
- Net Income Before Taxes
- 179.16
- Net Income
- 129.29
- Diluted Normalized EPS
- 11.57
- Period
- 2020
- Total Assets
- 978.61
- Total Liabilities
- 138.95
- Total Equity
- 839.65
- Tangible Book Valueper Share Common Eq
- 43.07
- Period
- 2020
- Cashfrom Operating Activities
- 140.9
- Cashfrom Investing Activities
- -44.5
- Cashfrom Financing Activities
- -38.55
- Net Changein Cash
- 59.6
- Period
- 2019
- Total Revenue
- 419.59
- Selling/ General/ Admin Expenses Total
- 133.1
- Depreciation/ Amortization
- 21.12
- Total Operating Expense
- 258.73
- Operating Income
- 160.86
- Net Income Before Taxes
- 161.96
- Net Income
- 111.06
- Diluted Normalized EPS
- 9.94
- Period
- 2019
- Total Assets
- 811.09
- Total Liabilities
- 132.25
- Total Equity
- 678.85
- Tangible Book Valueper Share Common Eq
- 30.4
- Period
- 2019
- Cashfrom Operating Activities
- 128.57
- Cashfrom Investing Activities
- -124.65
- Cashfrom Financing Activities
- -43.09
- Net Changein Cash
- -38.07
- Period
- 2025-03-31
- Total Revenue
- 167.18
- Selling/ General/ Admin Expenses Total
- 36.84
- Depreciation/ Amortization
- 10.08
- Other Operating Expenses Total
- 38.65
- Total Operating Expense
- 131.65
- Operating Income
- 35.53
- Net Income Before Taxes
- 43.46
- Net Income
- 26.48
- Diluted Normalized EPS
- 2.37
- Period
- 2025-03-31
- Total Assets
- 1621.35
- Total Liabilities
- 200.48
- Total Equity
- 1420.86
- Tangible Book Valueper Share Common Eq
- 92.52
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 142.5
- Cashfrom Investing Activities
- -89.1
- Cashfrom Financing Activities
- -72.54
- Net Changein Cash
- -19.53
- Period
- 2024-12-31
- Total Revenue
- 169.11
- Selling/ General/ Admin Expenses Total
- 34.52
- Depreciation/ Amortization
- 8.97
- Other Operating Expenses Total
- 40.5
- Total Operating Expense
- 122.83
- Operating Income
- 46.28
- Net Income Before Taxes
- 53.02
- Net Income
- 37.65
- Diluted Normalized EPS
- 3.36
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 146.1
- Selling/ General/ Admin Expenses Total
- 35.52
- Depreciation/ Amortization
- 8.9
- Other Operating Expenses Total
- 35.46
- Total Operating Expense
- 112.58
- Operating Income
- 33.52
- Net Income Before Taxes
- 42.21
- Net Income
- 32.83
- Diluted Normalized EPS
- 2.93
- Period
- 2024-09-30
- Total Assets
- 1549.18
- Total Liabilities
- 207.53
- Total Equity
- 1341.65
- Tangible Book Valueper Share Common Eq
- 85.63
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 42.96
- Cashfrom Investing Activities
- 3.28
- Cashfrom Financing Activities
- -62.36
- Net Changein Cash
- -15.97
- Period
- 2024-06-30
- Total Revenue
- 154.52
- Selling/ General/ Admin Expenses Total
- 34.66
- Depreciation/ Amortization
- 8.61
- Other Operating Expenses Total
- 34.45
- Total Operating Expense
- 111.97
- Operating Income
- 42.55
- Net Income Before Taxes
- 48.67
- Net Income
- 34.15
- Diluted Normalized EPS
- 3.05
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 157.82
- Selling/ General/ Admin Expenses Total
- 32.48
- Depreciation/ Amortization
- 9.28
- Other Operating Expenses Total
- 34.45
- Total Operating Expense
- 126.85
- Operating Income
- 30.96
- Net Income Before Taxes
- 39.61
- Net Income
- 28.31
- Diluted Normalized EPS
- 3.54
- Period
- 2024-03-31
- Total Assets
- 1535.46
- Total Liabilities
- 211.33
- Total Equity
- 1324.13
- Tangible Book Valueper Share Common Eq
- 84.11
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 141.37
- Cashfrom Investing Activities
- -64.65
- Cashfrom Financing Activities
- -59.24
- Net Changein Cash
- 17.33
- Period
- 2023-12-31
- Total Revenue
- 160.94
- Selling/ General/ Admin Expenses Total
- 32.13
- Depreciation/ Amortization
- 8.6
- Other Operating Expenses Total
- 39.99
- Total Operating Expense
- 115.78
- Operating Income
- 45.16
- Net Income Before Taxes
- 58.88
- Net Income
- 41.77
- Diluted Normalized EPS
- 3.74
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Advanced Enzyme Technologies Technical
Moving Average
SMA
- 5 Day329.37
- 10 Day330.95
- 20 Day320.77
- 50 Day302.8
- 100 Day298.46
- 300 Day361.25
Advanced Enzyme Technologies Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Rpg Life Sciences
- 2409
- -22.98
- -0.94
- 2971.79
- 1454.6
- 3964.78
- Dishman Carbogen Amcis
- 249.45
- 3.9
- 1.59
- 307.8
- 155
- 3870.76
- Advanced Enzyme Technologies
- 329
- 4.2
- 1.29
- 571.15
- 257.85
- 3678.62
- Orchid Pharma
- 708.95
- 5.65
- 0.8
- 1998
- 603.8
- 3599.82
- Gufic Biosciences
- 351
- -1.25
- -0.35
- 501.1
- 285
- 3519.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Rpg Life Sciences
- 34.16
- 7.61
- 28.51
- 16.68
- Dishman Carbogen Amcis
- 226.4
- 0.67
- -1.15
- -2.77
- Advanced Enzyme Technologies
- 27.95
- 2.58
- 11
- 22.95
- Orchid Pharma
- 35.8
- 2.82
- 2.14
- 2.75
- Gufic Biosciences
- 50.52
- 5.86
- 22.25
- 10.48
Advanced Enzyme Technologies Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 13-May-25
- Audited Results, Interim & Final Dividend
- 08-Feb-25
- Quarterly Results
- 09-Nov-24
- Quarterly Results
- 10-Aug-24
- Quarterly Results
- 11-May-24
- Audited Results & Dividend
- 10-Feb-24
- Quarterly Results
- 07-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 13-May-23
- Audited Results & Dividend
- 11-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 25-Jul-24
- 15-Jul-24
- AGM
- 12-Aug-23
- 13-May-23
- AGM
- 08-Sept-21
- 10-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 06-May-25
- 23-Jul-25
- 23-Jul-25
- 1.2
- 07-May-25
- 17-May-25
- 16-May-25
- 4
- 06-May-24
- 18-Jul-24
- 18-Jul-24
- 1.1
- 11-May-24
- 18-May-24
- 17-May-24
- 4
- 15-May-23
- 05-Aug-23
- 04-Aug-23
- 1
- 08-May-23
- 20-May-23
- 19-May-23
- 4
- 20-May-22
- 12-Aug-22
- 11-Aug-22
- 1
- 31-May-21
- 01-Sept-21
- 31-Aug-21
- 0.9


